Find a Clinical Trial by Adult Cancer Type

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

Back to Adult Cancers

Cancer Type: Breast

54 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Show: Only Breast specific trials All trials that include Breast

Doctor	Protocol No.	Title
Asher, Arash	IIT2019-07-ASHER-QIGONG	IIT2019-07-ASHER-QIGONG: A Mind-Body Intervention for Chemotherapy-Induced Peripheral Neuropathy (IRB#56)
Asher, Arash	IIT2018-05-ASHER-IMPROV2	IIT2018-05-ASHER-IMPROV2, It's All Improv after Cancer! A Randomized Clinical Trial Examining the Impact of an Improvisational Comedy Intervention on Well-Being among Patients with Cancer (IRB#56710)
Balmanoukian, Ani	M15-862	M15-862: A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects with Advanced Solid Tumors (IRB#46931)
Balmanoukian, Ani	M16-438	M16-438: A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands (IRB#49976)
Balmanoukian, Ani	204691	204691: A Phase I Open Label study of GSK3359609 administered alone and in combination with anticancer agents in subjects with selected advanced solid tumors (IRB:54166)
Balmanoukian, Ani	AB154CSP0001	AB154CSP0001: A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants with Advanced Malignancies (IRB#57210)
Balmanoukian, Ani	SGN228-001	A phase 1 study of SGN-CD228A in select advanced solid tumors (IRB#138)
Balmanoukian, Ani	GO39733	GO39733 : A phase IA/IB open-label, dose-escalation study of the safety and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic tumors (IRB#49235)
Basho, Reva	SGNLVA-002	SGNLVA 002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer (IRB#52102)
Boasberg, Peter D	4020-01-001	4020-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (IRB#49142)
Burnison, C Michele	A221505	A221505: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction (RT Charm) (IRB#54882)
Chung, Alice	IIT2018-28-CHUNG-VR4BR	VR 4 BR: Effects of Virtual Reality on Women Undergoing Mastectomy with Breast Reconstruction - A Pilot Study (IRB#55330)
Chung, Alice	IIT2015-06-CHUNG-SNBO	Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 65 (IRB#41396)
Freedland, Stephen	IIT2018-19-GRESH-DIGISTEP	Digitally-captured Step counts for Evaluating Performance Status in Advanced Cancer Patients: A single cohort, prospective trial (Digi-STEPS) (IRB#55271)
Gayther, Simon	1080	The Gilda Radner Hereditary Cancer Program (IRB#1080)
Giuliano, Armando	AFT-25	AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial (IRB#48166)
Gutierrez, Rodolfo	AB928CSP0005	A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies (IRB#55460)
Hamid, Omid	CART-TNMUC1-01	CART-TnMUC1-01: A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma (IRB#12345)
Hamid, Omid	CMIW815X2102J	CMIW815X2102J: A Phase Ib, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection with PDR001 to patients with advanced/metastatic solid tumors or lymphomas (IRB#49591)
Hamid, Omid	CTMX-M-072-001	An open-label, dose-finding and proof of concept study of the PD-L1 probody therapeutic, CX-072, as monotherapy and in combination with yervoy (ipilimumab) or with zelboraf (vemurafenib) in subjects with advanced or recurrent solid tumors or lymphomas (IRB#46401)
Hamid, Omid	D8510C00001	D8510C00001: A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors (IRB#57295)
Hamid, Omid	R3767-ONC-1613	R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies (IRB#48031)
Hamid, Omid	INCAGN2390-101	INCAGN2390-101: A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies (IRB#54179)
Hamid, Omid	NC318-01	NC318-01: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors (IRB#54833)
Hamid, Omid	587-00	587-00: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. (IRB#54410)
Hamid, Omid	TAPUR	Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119)
Hendifar, Andrew	MK-7339-002	MK7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (IRB#57241)
Hendifar, Andrew	MK-7902-005	MK-7902-005: A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (IRB#0057697)
Hitchins, Megan	IIT2017-13-HITCHINS-UCFC	IIT2017-13-HITCHINS-UCFC: Identifying cryptic causes for high-risk hereditary cancer syndromes and their role in cancer causation. (IRB#49624)
Karlan, Scott	EIIT-NWU2017-09-01	EIIT-NWU2017-09-01: Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery (IRB52580)
Labadzhyan, Artak	IIT2016-09-LABADZHYAN-ICI	IIT2016-09-LABADZHYAN-ICI: Prospective study of predictive markers and changes in specific endocrine hormones in patients with metastatic cancers treated with immune checkpoint inhibitors. (IRB#45026)
McArthur, Heather	IIT2018-01-MCARTHUR-IPI	IIT2018-01-McArthur-IPI: A Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer (IRB#52157)
McArthur, Heather	IIT2018-04-MCARTHUR-NEOHP	IIT2018-04-MCARTHUR-NEOHP: Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab (IRB#53566)
McArthur, Heather	MK3475-756	MK3475-756: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2 ) Breast Cancer (IRB#57046)
McArthur, Heather	BIG16-05/AFT-27/WO39391	BIG 16-05/AFT-27/WO39391: A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMPASSION030 AFT-27) (IRB#53409)
Mita, Monica	MCLA-128-CL02	MCLA-128-CL02: Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC (IRB#52060)
Mita, Monica	MT-5111-001	MT-5111_001: A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (IRB#144)
Mita, Monica	RGX-104-001	A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (IRB#46271)
Mita, Monica	NP-102	NP-102: A Phase I, Open-Label Study of the Safety, Pharmacokinetics and Efficacy of RX108 in Patients with Locally Advanced or Metastatic Solid Tumors (IRB# 52576)
Mita, Alain	XMAB20717-01	XmAb20717-01: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (IRB #53244)
Mita, Monica	1381-1	1381.1: An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics, and efficacy of BI 754091 in patients with advanced solid tumors (IRB#053757)
Mita, Monica	IIT2015-20-MITA-CSMCMATCH	Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute (IRB#44912)
Mita, Monica	GEN-602-CT-101	GEN-602-CT-101: A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Given orally on a daily x 21 days followed by 7 Days off schedule in patients with Advanced Solid Tumors or Lymphoma (IRB#56184)
Mita, Alain	EAY131	EAY131: Molecular Analysis for Therapy Choice (MATCH) (IRB#41419)
Mita, Monica	C0541001	C0541001: A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor (HER2) Positive Solid Tumors (IRB#51035)
Mita, Monica	ASTX660-01	ASTX660-01: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (IRB#40980)
Mita, Alain	ASTX029-01	ASTX029-01: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors (IRB#54467)
Mita, Alain	8374-CL-0101	8374-CL-0101: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (IRB#55959)
Posadas, Edwin	BB-UOP-42197-BLOOD-BANK	Urologic Oncology Program Blood Specimen Repository (IRB # 42197)
Ray, Edward	IIT2018-08-RAY-TEBREAST	IIT2018-08-RAY-TEBREAST: Tissue Expansion in Breast Reconstruction Without Drains (IRB#52823)
Shiao, Stephen	IIT2017-07-HO-PEMBRORT	IIT2017-07-HO-PEMBRORT: Pilot Study of the Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients with Operable Breast Cancer (IRB#49440)
Shiao, Stephen	IIT2015-07-SHIAO-HIFIDELI	Novel High Fidelity Functional Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis (IRB#43055)
Shiao, Stephen	IIT2016-18-SHIAO-NEOADSRS	IIT2016-18-SHIAO-NEOADSRS: Neoadjuvant radiosurgery for the treatment of metastatic brain tumors (IRB#47027)
Wentzel, Kristopher	XL184-021	XL184-021: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (IRB#56332)

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Phase I

Researchers test an experimental drug or treatment in a small group of people (20-80), to evaluate its safety and identify side effects. Often these trials are not disease specific and may include more than one type of cancer.

Phase II

The experimental drug or treatment is administered to a larger group of people (100-300) to determine its effectiveness and to further evaluate its safety.

Phase III

The experimental drug or treatment is administered to larger groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatment, and collect information that will allow the experimental drug or treatment to be used safely.